GSK Announces Approval And Availability Of Avandaryl(TM) (rosiglitazone Maleate

GSK Announces Approval And Availability Of Avandaryl(TM) (rosiglitazone Maleate And Glimepiride)

Avandaryl is the first and only tablet to combine a thiazolidinedione (TZD), rosiglitazone maleate – separately marketed as Avandia(R) – with a sulfonylurea, glimepiride – separately marketed as Amaryl(R) – to help improve blood sugar control.

GlaxoSmithKline announces the availability of Avandaryl(TM) (rosiglitazone maleate and glimepiride), a new fixed-dose combination product for type 2 diabetes. As an adjunct to diet and exercise, Avandaryl is indicated to improve blood sugar control in patients with type 2 diabetes who are already treated with a combination of rosiglitazone and sulfonylurea or who are not adequately controlled on a sulfonylurea alone or for those patients who have initially responded to rosiglitazone alone and require additional blood sugar control.

“An estimated 64 percent of type 2 diabetes patients are not well controlled on their current therapy. According to the United Kingdom Prospective Diabetes Study (UKPDS), many monotherapy treatments may fail to maintain blood sugar control over time.

To reach recommended blood sugar levels, many people with type 2 diabetes may eventually need to take more than one medicine to help treat the disease in different ways. To manage diabetes, it is important for patients, along with their physicians, to set and meet A1c goals.

Avandaryl is the first fixed-dose combination tablet containing a TZD and a sulfonylurea. This medication combines rosiglitazone, the most widely prescribed TZD compound, with glimepiride, a second-generation member of the sulfonylurea class of oral diabetes therapies. As an adjunct to diet and exercise, Avandaryl is indicated to improve blood sugar control in patients with type 2 diabetes who are already treated with a combination of rosiglitazone and sulfonylurea or who are not adequately controlled on a sulfonylurea alone or for those patients who have initially responded to rosiglitazone alone and require additional blood sugar control.

Avandaryl, which offers convenient dosing, is available in three tablet strengths of rosiglitazone/glimepiride, respectively: 4 mg/1 mg, 4 mg/2 mg and 4 mg/4 mg.

For more information about Avandaryl, www.avandia.com .

================================

DID YOU KNOW:
Coffee decreases the risk of developing type 2 diabetes in younger and middle-aged US women, according to the results of a large, prospective cohort study reported in the February issue of Diabetes Care.